Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.35 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358617 | 0.83 | RAD51 (0.47) | EPHX2NR1H4BRPF1HDAC4OPRM1 | |
| SCHEMBL14358811 | 0.79 | EPHX2 (0.43) | EPHX2NR1H4 | |
| SCHEMBL15105722 | 0.78 | ENPP2 (0.51) | EPHX2NR1H4BRPF1HDAC4OPRM1 | |
| SCHEMBL14361624 | 0.78 | ENPP2 (0.51) | EPHX2NR1H4BRPF1HDAC4OPRM1 | |
| SCHEMBL14361580 | 0.75 | HPGD (0.48) | — | |
| SCHEMBL14358859 | 0.75 | EPHX2 (0.46) | EPHX2NR1H4BRPF1BRD4EGFR | |
| SCHEMBL9079841 | 0.73 | EGFR (0.41) | EGFR | |
| SCHEMBL14358903 | 0.73 | ENPP2 (0.46) | EPHX2NR1H4BRPF1HDAC4OPRM1 | |
| SCHEMBL14358499 | 0.73 | ENPP2 (0.49) | EPHX2NR1H4BRPF1HDAC4OPRM1 | |
| SCHEMBL14358905 | 0.73 | ENPP2 (0.46) | EPHX2NR1H4BRPF1HDAC4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | claimed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | claimed |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | EPHX2 1035/4885NR1H4 3462/4885BRPF1 1428/4885 |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | BAK1, SSB, MRE11 | EPHX2 1035/4885NR1H4 3462/4885BRPF1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.